Treatment-resistant Schizophrenia
22
7
8
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
13.6%
3 terminated out of 22 trials
66.7%
-19.8% vs benchmark
27%
6 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (22)
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
Deep Brain Stimulation in Treatment Resistant Schizophrenia
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
Neural Biomarkers of Clozapine Response
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Hippocampus DBS in Treatment-resistant Schizophrenia
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia